21.4 C
New York
Thursday, June 4, 2026

Tag: Peter

Grant & Eisenhofer Representing Dozens of Rhode Island Clergy Sexual-Abuse Survivors Amid Long-Awaited Legislative Reform

GRANT & EISENHOFER FIRM REPRESENTING DOZENS OF RHODE ISLAND CLERGY SEXUAL-ABUSE SURVIVORS AMID LONG-AWAITED LEGISLATIVE REFORM

A2GOLD ANNOUNCES HIGH-GRADE GOLD AND SILVER SURFACE CHANNEL RESULTS FROM BLACKROCK TARGET

CORE DRILLING ONGOING AT CASTLE ZONE (EASTSIDE)TONOPAH, NEV., June 3, 2026 /CNW/ - A2Gold Corp. ("A2Gold" or the "Company") (TSXV: AUAU) (OTCQX: AUXXF) (FRA: RR7)...

TRREB Welcomes Launch of Ontario–Canada Development Charges Reduction Program

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- The Toronto Regional Real Estate Board (TRREB) welcomed the launch of the Ontario–Canada Development Charges Reduction Program, calling it a major step toward lowering housing costs, improving project viability, and accelerating the construction of much-needed homes across the Greater Golden Horseshoe.

David Launches High-Protein Frozen Dessert

Following its June 1 online launch, David Frozen Dessert sold out in 28 minutes.The brand's newest innovation brings its signature protein-per-calorie efficiency to the...

Viasat Releases Fourth Quarter and Fiscal Year 2026 Financial Results

Viasat, Inc., a global leader in satellite communications, today published its fourth quarter and fiscal year 2026 financial results.

Associated Capital Group, Inc. Announces Voluntary NYSE Delisting and SEC Deregistration

GREENWICH, Conn., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (NYSE: AC) (“AC” or the “Company”) announced today that it has given formal notice to the New York Stock Exchange (“NYSE”) of its intention to voluntarily delist its Class A common stock (the “common stock”) from the NYSE and to deregister under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). Following the de-listing from the NYSE, we expect to provide liquidity to AC’s Class A stock shareholders by listing AC Class A on the OTCQX platform (the “OTCQX”). AC plans on filing a Form 25 with the U.S. Securities and Exchange Commission (the “SEC”) on or about August 25, 2025. The last day of trading in AC’s common stock on the NYSE will be on or about September 4, 2025, when the Form 25 takes effect. Ninety days thereafter, AC’s common stock deregistration is expected to become effective. When AC files Form 15 on or about September 4, 2025, its filing obligations under the Exchange Act will immediately be suspended or terminated, including the filing of all reports on Forms 8-K, 10-Q and 10-K.

Anmodning om suspension for andelsklasser under Investeringsforeningen BankInvest

På grund af lokale børslukkedage i underliggende markeder anmodes om suspension af nedenstående andelsklasser.

City of Rochelle, IL Expands Rochelle Intermodal Transload Center

ROCHELLE, Ill., Aug. 14, 2025 /PRNewswire/ -- Today, representatives from the City of Rochelle, IL, along with state transportation officials, local economic partners, railroad, and...

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX

Peace One Day Transforms Peace Day, 21 September 2025 into the World’s Largest Online Festival for Peace

LONDON, Aug. 14, 2025 /PRNewswire/ -- Peace One Day today announces that its planned 21 September 2025 celebration at the OVO Arena Wembley will now...

KARNALYTE RESOURCES INC. ANNOUNCES 2025 SECOND QUARTER RESULTS AND CORPORATE HIGHLIGHTS

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ SASKATOON, SK, Aug. 13, 2025 /CNW/ - Karnalyte Resources Inc. ("Karnalyte"...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPeter